This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Nektar Presents Positive Proof-of-Concept Clinical Data For Its New Opioid Molecule, NKTR-181, At American Academy Of Pain Medicine's 28th Annual Meeting

SAN FRANCISCO, Feb. 27, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced a presentation of positive clinical data for NKTR-181, its new oral opioid analgesic molecule, at the 2012 American Academy of Pain Medicine's 28th Annual Meeting (AAPM). NKTR-181 is a novel mu-opioid agonist molecule, which was designed to have a slow rate of entry into the brain to reduce the attractiveness of the molecule as a target of abuse and to reduce its CNS-mediated side effects. NKTR-181 was created using Nektar's proprietary polymer conjugate technology and its differentiating properties are inherent to the design of the new molecule.  As a new molecular structure, NKTR-181 is unique in that it does not rely on a formulation approach to prevent its conversion into a more abusable form of an opioid.

Clinical results were presented at AAPM from a human Phase 1 study which evaluated the pharmacokinetics, pharmacodynamics, and safety of oral doses of NKTR-181 as compared to placebo over an 8-day treatment period in healthy subjects.  Using pupil constriction as a measure of the onset of central opioid effect, the study showed that NKTR-181 enters the brain slowly and produces centrally-mediated opioid effects that are dose-dependent and statistically meaningful (P<0.001) following twice daily oral doses of 200-400 mg.  Further, NKTR-181 enters the CNS from the plasma at a rate approximately ten-times slower than historical published rates for oxycodone.(1)  NKTR-181's slow rate of entry into the CNS may reduce the euphoria and other CNS side effects that are associated with rapid CNS uptake of current standard opioid therapies. 

"NKTR-181 is an exciting new approach to opioid analgesia," said Lynn R. Webster, MD, Medical Director of Lifetree Clinical Research. "The human data now show us that NKTR-181 crosses into the brain slowly across a wide range of doses, over multiple days of dosing, and also achieves a sustained analgesic response.  By slowing the rate of entry into the brain, NKTR-181 is designed to have less euphoria, sedation and respiratory depression than traditional opioid compounds. Individuals with a higher risk of abusing opioids prefer rapid onset of euphoria, which means NKTR-181 should be less attractive as a drug of abuse.  NKTR-181 represents an exciting developmental advance in pain.  This new human data support its further clinical development as a compelling therapeutic for the treatment of chronic pain."

Data presented at AAPM show the positive analgesic properties of NKTR-181 in humans. NKTR-181 produced dose-dependent analgesic responses in two separate models of pain used to measure central and peripheral analgesic activity in healthy subjects.  In a cold-pressor test pain model measuring latency-to-hand-removal (LHR), the 200 mg dose of NKTR-181 given twice-daily over the 8-day dosing period demonstrated the extent and duration of analgesic effect of NKTR-181 administration.  Results show a significant analgesic effect as compared to placebo (P<0.01, n=12) over the entire dosing period.  In addition, a model of induced UVB injury was also used to demonstrate the extent and duration of analgesic effect produced by NKTR-181.  Results show that NKTR-181 has both centrally-mediated and peripherally-mediated analgesic effects.  In this model, data was presented on NKTR-181 at doses of 300 mg and 400 mg demonstrating its significant analgesic and anti-hyperalgesic effect (measured as change from baseline) following mechanical and thermal stimulation, with p-values of P<0.009 and P<0.03, respectively (n=12). 

1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.24 -0.99%
FB $118.03 0.51%
GOOG $697.46 0.74%
TSLA $228.74 -1.50%
YHOO $35.90 -0.31%


Chart of I:DJI
DOW 17,651.16 -99.75 -0.56%
S&P 500 2,050.19 -13.18 -0.64%
NASDAQ 4,727.0170 -36.2070 -0.76%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs